- Home
- NDLS vs RVPH Comparison
NDLS vs RVPH Comparison
Compare NDLS & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- RVPH
- Stock Information
- Founded
- NDLS 1995
- RVPH 2006
- Country
- NDLS United States
- RVPH United States
- Employees
- NDLS N/A
- RVPH N/A
- Industry
- NDLS Restaurants
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- RVPH Health Care
- Exchange
- NDLS Nasdaq
- RVPH Nasdaq
- Market Cap
- NDLS 32.9M
- RVPH 32.8M
- IPO Year
- NDLS 2013
- RVPH N/A
- Fundamental
- Price
- NDLS $0.80
- RVPH $0.38
- Analyst Decision
- NDLS Strong Buy
- RVPH Strong Buy
- Analyst Count
- NDLS 2
- RVPH 5
- Target Price
- NDLS $3.00
- RVPH $9.00
- AVG Volume (30 Days)
- NDLS 212.2K
- RVPH 2.8M
- Earning Date
- NDLS 08-06-2025
- RVPH 08-13-2025
- Dividend Yield
- NDLS N/A
- RVPH N/A
- EPS Growth
- NDLS N/A
- RVPH N/A
- EPS
- NDLS N/A
- RVPH N/A
- Revenue
- NDLS $495,670,000.00
- RVPH N/A
- Revenue This Year
- NDLS $5.37
- RVPH N/A
- Revenue Next Year
- NDLS $0.68
- RVPH N/A
- P/E Ratio
- NDLS N/A
- RVPH N/A
- Revenue Growth
- NDLS N/A
- RVPH N/A
- 52 Week Low
- NDLS $0.55
- RVPH $0.30
- 52 Week High
- NDLS $1.83
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- NDLS 52.86
- RVPH 31.86
- Support Level
- NDLS $0.66
- RVPH $0.35
- Resistance Level
- NDLS $0.82
- RVPH $0.83
- Average True Range (ATR)
- NDLS 0.07
- RVPH 0.06
- MACD
- NDLS 0.01
- RVPH -0.02
- Stochastic Oscillator
- NDLS 87.67
- RVPH 14.45
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.